Ligand Pharmaceuticals LGND Tolerance Therapeutics (Tzield®) — Financial Royalty Assets, Net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsNet.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's tolerance therapeutics (tzield®) — financial royalty assets, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's tolerance therapeutics (tzield®) — financial royalty assets, net?
- Ligand Pharmaceuticals (LGND) reported tolerance therapeutics (tzield®) — financial royalty assets, net of $25.07M in Q1 2026.
- What does tolerance therapeutics (tzield®) — financial royalty assets, net mean?
- This metric represents the net book value of the royalty asset related to the Tzield product after accounting for all applicable allowances and impairments. It serves as the current carrying value of the asset on the balance sheet, reflecting the estimated present value of future royalty cash flows. This figure is critical for assessing the tangible value of the company's intellectual property portfolio and its potential for future cash generation.